Merck
  • Home
  • Search Results
  • Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy.

Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy.

Cancer discovery (2019-11-09)
Claudia X Dominguez, Sören Müller, Shilpa Keerthivasan, Hartmut Koeppen, Jeffrey Hung, Sarah Gierke, Beatrice Breart, Oded Foreman, Travis W Bainbridge, Alessandra Castiglioni, Yasin Senbabaoglu, Zora Modrusan, Yuxin Liang, Melissa R Junttila, Christiaan Klijn, Richard Bourgon, Shannon J Turley
ABSTRACT

With only a fraction of patients responding to cancer immunotherapy, a better understanding of the entire tumor microenvironment is needed. Using single-cell transcriptomics, we chart the fibroblastic landscape during pancreatic ductal adenocarcinoma (PDAC) progression in animal models. We identify a population of carcinoma-associated fibroblasts (CAF) that are programmed by TGFβ and express the leucine-rich repeat containing 15 (LRRC15) protein. These LRRC15+ CAFs surround tumor islets and are absent from normal pancreatic tissue. The presence of LRRC15+ CAFs in human patients was confirmed in >80,000 single cells from 22 patients with PDAC as well as by using IHC on samples from 70 patients. Furthermore, immunotherapy clinical trials comprising more than 600 patients across six cancer types revealed elevated levels of the LRRC15+ CAF signature correlated with poor response to anti-PD-L1 therapy. This work has important implications for targeting nonimmune elements of the tumor microenvironment to boost responses of patients with cancer to immune checkpoint blockade therapy. SIGNIFICANCE: This study describes the single-cell landscape of CAFs in pancreatic cancer during in vivo tumor evolution. A TGFβ-driven, LRRC15+ CAF lineage is associated with poor outcome in immunotherapy trial data comprising multiple solid-tumor entities and represents a target for combinatorial therapy.This article is highlighted in the In This Issue feature, p. 161.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
牛血清白蛋白 来源于牛血清, lyophilized powder, ≥96% (agarose gel electrophoresis)
Sigma-Aldrich
OptiPrep密度梯度培养基, used for cell and subcellular organelle isolation
Sigma-Aldrich
透明质酸酶 来源于牛睾丸, Type I-S, lyophilized powder, 400-1000 units/mg solid
Sigma-Aldrich
胶原酶 来源于溶组织梭菌, for general use, Type I, 0.25-1.0 FALGPA units/mg solid, ≥125 CDU/mg solid
Sigma-Aldrich
Gey′s平衡盐溶液, liquid, sterile-filtered, suitable for cell culture
Sigma-Aldrich
人血清, from platelet poor human plasma, sterile-filtered, (mycoplasma tested, virus tested)
Sigma-Aldrich
钙黄绿素蓝